James Karas
Cardiovascular Disease · Thomasville, GANPI 1881696110
Payments from drug & device makers
Across 262 payments — averaging $17.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$874
- Novartis$616
- Abbott$535
- Amgen$532
- Pfizer$394
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$277
- plus $1K from 18 others
What the payments were for
- Food & beverage$4,52998%
- Education$922%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 57 | $874 |
| Novartis | 43 | $616 |
| Abbott | 8 | $535 |
| Amgen | 36 | $532 |
| Pfizer | 30 | $394 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 20 | $277 |
| Amarin Pharma, Inc. | 9 | $229 |
| Merck | 8 | $137 |
| Sanofi-aventis U.S. LLC | 6 | $120 |
| Arbor Pharmaceuticals, Inc. | 7 | $116 |
| Medtronic(2 entities) | 4 | $109 |
| Boehringer Ingelheim | 1 | $108 |
| E.r. Squibb & Sons, L.L.C. | 8 | $104 |
| AstraZeneca | 2 | $92 |
| Novo Nordisk | 5 | $80 |
| Regeneron Healthcare Solutions, Inc. | 3 | $53 |
| Kowa Pharmaceuticals America, Inc. | 3 | $46 |
| Esperion Therapeutics, Inc. | 2 | $44 |
| Bayer | 3 | $42 |
| Alnylam Pharmaceuticals Inc. | 2 | $42 |
| Boston Scientific | 2 | $33 |
| Portola Pharmaceuticals, LLC | 1 | $15 |
| Actelion Pharmaceuticals US, Inc. | 1 | $12 |
| Amryt Pharma Holdings Ltd | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$229
- CardioMEMS HF System$182
- CARDIOMEMS$148
- Vascepa$112
- JARDIANCE$108
How this compares
$4,621 in reported general payments places this provider in the 65th percentile of 640 cardiovascular disease providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 20 | $11,828 |
| Atorvastatin Calcium | 27 | $336 |
| ClopidogrelClopidogrel Bisulfate | 13 | $250 |
| Metoprolol Succinate | 13 | $245 |
| Hydralazine Hcl | 16 | $204 |
| Lisinopril | 21 | $118 |
| Carvedilol | 23 | $99 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $394 | $11,82820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 640 cardiovascular disease providers in Georgia.
Other cardiovascular disease in Thomasville
- Kashyap ChoksiThomasville$283K
- Narendra SinghJohns Creek$5.4M
- Elizabeth OfiliAtlanta$4.5M
- Sanjay YadavAtlanta$3.7M
- Arshed QuyyumiAtlanta$3.4M
- Naresh ParikhNorcross$2.8M
- Nicolas ChronosEatonton$2.4M
- Bobby KhanAtlanta$1.7M
- Hunter ChampionColumbus$1.5M
- David SuhTucker$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.